Biotech product

Brain-computer interfaces

BCIs crossed from lab to early commercial reality between 2024 and 2026: Neuralink put 5+ patients on the Telepathy implant, Precision Neuroscience took home the first wireless-cortical-BCI 510(k), BrainGate hit 110 cpm bimanual typing, UCSF restored speech at 78 wpm, and Meta shipped a 20.9 wpm sEMG wristband to consumers.

What to watch next

The first BCI Pre-Market Approval (likely Synchron), Neuralink's first Blindsight implant, Paradromics speech-restoration pivotal results, and whether the non-invasive consumer category (Meta Neural Band, Kernel) closes meaningful ground on invasive bandwidth.

Key sub-ideas & techniques

• Intracortical microelectrode arrays (Utah arrays) — High-density silicon arrays implanted directly into motor cortex (Blackrock NeuroPort) record from individual neurons — the gold standard for invasive BCIs since the early 2000s. [source]
• Endovascular BCI (Stentrode) — Synchron's stent-electrode is implanted via blood vessels — no open-brain surgery — trading some signal fidelity for dramatically lower surgical risk. [source]
• High-bandwidth thin-film cortical interfaces — Flexible subdural electrode films (e.g. Precision Layer 7) put 1,024+ electrodes on a hair-thin sheet, with FDA 510(k) clearance and a Medtronic surgical-navigation partnership in 2025–26. [source]
• Speech decoding & synthesis — UCSF's Chang lab and Stanford have pushed motor-cortex speech decoders to 78 wpm with personalized voice synthesis; the BrainGate consortium hit 110 cpm bimanual typing. [source]
• Non-invasive consumer BCI (EMG / EEG / fNIRS) — Wearable surface-EMG and EEG/fNIRS systems (Meta Neural Band, Kernel Flow, OpenBCI) are reaching consumer scale at meaningful — if lower — bandwidths than invasive devices. [source]
• Intraoperative high-density micro-ECoG BCI — Temporary high-density micro-electrocorticography arrays placed during routine awake craniotomy that yield same-day speech and cursor decoding, lowering the barrier to BCI use in surgical mapping and short-term clinical applications. [source]

Current frontier

• Neuralink's PRIME trial has implanted 5+ patients across multiple sites by mid-2025; the second patient ('Alex') achieved CAD control and gaming within days, and Blindsight (visual prosthesis) received FDA breakthrough device designation (Sep 2024) with first-in-human implant planned for 2026. [source]
• Paradromics received FDA IDE approval (Nov 2025) for the Connect-One speech-restoration trial with the Connexus BCI, claiming ~200+ bps information transfer (10–20× higher than BrainGate, 100–200× higher than Synchron) via thread arrays thinner than a human hair. [source]
• INBRAIN Neuroelectronics completed enrollment for the world's first graphene-BCI clinical trial (April 2026) with zero device-related adverse events in the first cohort; 1,024-contact wireless rechargeable arrays. [source]
• Precision Neuroscience's Layer 7 received FDA 510(k) clearance (April 2025) — the first wireless cortical BCI cleared for market — and is now in 30-day chronic trials at six U.S. medical centers; Medtronic partnership announced January 2026. [source]
• BrainGate reported rapid bimanual typing (110 cpm, 1.6% WER) in two paralyzed patients (Nature Neuroscience, March 2026); the consortium raised $200M Series D in late 2025 for FDA PMA pivotal trials. [source]
• Neuralink developing surgical robot for precision brain access with automated procedures and high-volume implant production targeted for 2026. [source]
• Synchron's Stentrode is the first BCI integrated with Apple's BCI HID profile as a native input category, enabling hands-free Apple-device control for paralysis patients. [source]
• Neuralink is developing a next-generation surgical robot capable of implanting threads in any brain region, paired with a 2026 push to high-volume implant manufacturing. [source]

Key people

• Leigh Hochberg Director, Center for Neurotechnology and Neurorecovery; IDE sponsor-investigator, BrainGate · Brown University / Massachusetts General Hospital [source]
• Edward Chang Director, Speech Neuroprosthesis Lab · UCSF Department of Neurosurgery [source]
• Jaimie Henderson Director, Stanford Neural Prosthetics Translational Lab; Co-PI, BrainGate2 · Stanford School of Medicine [source]
• Thomas Oxley Co-founder & CEO · Synchron Inc. [source]
• Matt Angle Founder & CEO · Paradromics [source]
• Benjamin Rapoport Co-founder & Chief Science Officer · Precision Neuroscience [source]

Startups & labs to watch

• Neuralink Blindsight Neuralink · STARTUP · Reported $1B+ private equity, Musk-led — First visual-prosthesis implant planned in 2026 — direct visual-cortex stimulation that bypasses damaged optics. A major expansion from motor-only BCIs. [source]
• Synchron pivotal trial Synchron Inc. · STARTUP · $200M raise (Nov 2025) for pivotal trial execution — Preparing FDA Pre-Market Approval submission across 4+ U.S. sites; if approved, the first BCI PMA could define the regulatory gold standard for the field. [source]
• Paradromics Connexus Paradromics Inc. · STARTUP · Series-stage venture funding (specifics undisclosed) — Extreme bandwidth (~200+ bps), first FDA IDE for speech restoration as a primary endpoint, 3 clinical sites planned for early 2026. [source]
• INBRAIN Neuroelectronics INBRAIN (Barcelona) · STARTUP · Spanish/EU biotech funding; WEF recognition signals next round — Graphene-electrode material breakthrough with bi-directional 1,024-contact arrays; WEF Technology Pioneer 2025 and zero adverse events in first cohort. [source]
• Rice/Baylor BrainGate team Rice University & Baylor College of Medicine · LAB · Federal/clinical trial grants (BrainGate consortium) — First Texas-based BrainGate site; pairs Rice computational/engineering with Baylor clinical neuroscience to advance intracortical BCI for tetraplegia assistive robotics. [source]